LINSITINIB Insulin-like Growth Factor 1 Receptor Antagonist Insulin Receptor Antagonist Oncolytic

被引：0

作者：

Bowles, Daniel W. ^{[1
]}

Kessler, Elizabeth R. ^{[1
]}

Jimeno, Antonio ^{[1
]}

机构：

[1] Univ Colorado Denver, Div Med Oncol, Aurora, CO 80045 USA

来源：

DRUGS OF THE FUTURE | 2011年 / 36卷 / 12期

关键词：

Prop INN; USAN; GROWTH-FACTOR-I; RECEPTOR KINASE INHIBITOR; COLORECTAL-CANCER; INSULIN-RECEPTOR; BREAST-CANCER; PLASMA-LEVELS; PHASE-II; RISK; OVEREXPRESSION; CHEMOTHERAPY;

D O I：

10.1358/dof.2011.036.12.1638802

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

Linsitinib (OSI-906) is a novel, small-molecule, dual inhibitor of insulin-like growth factor 7 receptor (IGT-I receptor) and insulin receptor (IR). There is ample evidence that the ICE-I receptor is overexpressed in several epithelial and mesenchymal malignancies. Preclinical data support linsitinib as a single agent or in combination with cytotoxic chemotherapy for colorectal carcinoma, adrenocortical carcinoma and breast carcinoma, among other cancers. This review will evaluate the preclinical pharmacology, pharmacokinetics, drug interactions and clinical activity in phase I through phase Ill studies.

引用

页码：881 / 891

页数：11